A healthy pipeline of innovative, high-quality generic products is vital for ATCO to sustain its position as one of the leading company in the local and export markets. Our Business Development department is vigilant in identifying the potential new molecules for development. The R&D department is adequately equipped for laboratory-scale experimental batches of different dosage forms.
Pilot batches are manufactured and monitored under strict production environments using production equipments and procedures.
Rationale for the selection of excipients used in the formulation is carefully reviewed to ensure that the efficacy and stability of the finished product is intact.
Samples from experimental and pilot batches are packed in simulated market packs and the stability of the product is determined as per protocol, which is based on the ICH guidelines and recommendations. Validated test methods are used for assay of APIs and their impurities.
